356 related articles for article (PubMed ID: 21481088)
21. Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome.
Ates S; Aydın S; Ozcan P; Soyman Z; Gokmen Karasu AF; Sevket O
J Obstet Gynaecol; 2018 Feb; 38(2):236-240. PubMed ID: 28920502
[TBL] [Abstract][Full Text] [Related]
22. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria.
Goverde AJ; van Koert AJ; Eijkemans MJ; Knauff EA; Westerveld HE; Fauser BC; Broekmans FJ
Hum Reprod; 2009 Mar; 24(3):710-7. PubMed ID: 19095675
[TBL] [Abstract][Full Text] [Related]
23. Low estradiol-to-testosterone ratio is associated with oligo-anovulatory cycles and atherogenic lipidic pattern in women with polycystic ovary syndrome.
Amato MC; Verghi M; Nucera M; Galluzzo A; Giordano C
Gynecol Endocrinol; 2011 Aug; 27(8):579-86. PubMed ID: 20608809
[TBL] [Abstract][Full Text] [Related]
24. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
[TBL] [Abstract][Full Text] [Related]
25. Ovarian morphology and endocrine function in polycystic ovary syndrome.
Tena G; Moran C; Romero R; Moran S
Arch Gynecol Obstet; 2011 Dec; 284(6):1443-8. PubMed ID: 21243502
[TBL] [Abstract][Full Text] [Related]
26. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in the Croatian population.
Baldani DP; Skrgatić L; Simunić V; Zlopasa G; Canić T; Trgovcić I
Coll Antropol; 2013 Jun; 37(2):477-82. PubMed ID: 23940993
[TBL] [Abstract][Full Text] [Related]
28. The Role of Anti-Müllerian Hormone in the Characterization of the Different Polycystic Ovary Syndrome Phenotypes.
Romualdi D; Di Florio C; Tagliaferri V; De Cicco S; Gagliano D; Immediata V; Lanzone A; Guido M
Reprod Sci; 2016 May; 23(5):655-61. PubMed ID: 26718304
[TBL] [Abstract][Full Text] [Related]
29. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
[TBL] [Abstract][Full Text] [Related]
30. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
Brzozowska MM; Ostapowicz G; Weltman MD
J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
[TBL] [Abstract][Full Text] [Related]
31. Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome.
Androulakis II; Kandaraki E; Christakou C; Karachalios A; Marinakis E; Paterakis T; Diamanti-Kandarakis E
Clin Endocrinol (Oxf); 2014 Sep; 81(3):426-31. PubMed ID: 24601936
[TBL] [Abstract][Full Text] [Related]
32. Adolescents diagnosed with polycystic ovary syndrome under the Rotterdam criteria but not meeting the diagnosis under the updated guideline.
Kim JJ; Hwang KR; Lee D; Kim S; Choi YM
Hum Reprod; 2024 May; 39(5):1072-1077. PubMed ID: 38514450
[TBL] [Abstract][Full Text] [Related]
33. Impact of the newly recommended antral follicle count cutoff for polycystic ovary in adult women with polycystic ovary syndrome.
Kim JJ; Hwang KR; Chae SJ; Yoon SH; Choi YM
Hum Reprod; 2020 Mar; 35(3):652-659. PubMed ID: 32211797
[TBL] [Abstract][Full Text] [Related]
34. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
35. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype.
Bil E; Dilbaz B; Cirik DA; Ozelci R; Ozkaya E; Dilbaz S
J Obstet Gynaecol Res; 2016 Jul; 42(7):837-43. PubMed ID: 27071345
[TBL] [Abstract][Full Text] [Related]
36. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
37. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome?
Catteau-Jonard S; Bancquart J; Poncelet E; Lefebvre-Maunoury C; Robin G; Dewailly D
Ultrasound Obstet Gynecol; 2012 Aug; 40(2):223-9. PubMed ID: 22648908
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome.
Lankarani M; Valizadeh N; Heshmat R; Peimani M; Sohrabvand F
Gynecol Endocrinol; 2009 Aug; 25(8):504-7. PubMed ID: 19499403
[TBL] [Abstract][Full Text] [Related]
39. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria.
Yildiz BO; Bozdag G; Yapici Z; Esinler I; Yarali H
Hum Reprod; 2012 Oct; 27(10):3067-73. PubMed ID: 22777527
[TBL] [Abstract][Full Text] [Related]
40. Effect of obesity on the clinical and hormonal characteristics of the polycystic ovary syndrome.
Singh KB; Mahajan DK; Wortsman J
J Reprod Med; 1994 Oct; 39(10):805-8. PubMed ID: 7837128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
